Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer
- PMID: 7551935
- DOI: 10.1016/0169-5002(95)00421-v
Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer
Abstract
The observation that the proteins encoded by ras genes play a central role in the signalling pathways used by cells to respond to growth factors and the fact that mutated ras proteins are constantly promoting cell division have led to a PCR-based hunt for additional clinical information. In the present study, K-ras analysis draws the following conclusions: (1) K-ras point mutation frequency was higher in the surgery group (10 of 24 patients) than in the chemotherapy-surgery group (3 of 20 patients). (2) Mutated K-ras was predominantly observed at codon 12 but five mutations appeared at codon 61. (3) Mutations were identified in the squamous cell carcinoma histological NSCLC subtype except in four cases corresponding to adenocarcinoma. (4) A multifarious pattern of substitutions, especially at codon 12, were noted with aspartic K 12 substitutions more prone to develop bone metastases. (5) Although a genotypic K-ras classification of NSCLC may not yet be formulated, our accumulated data (unpublished) suggest a trend toward it. (6) Patients with mutated K-ras tumors in the surgery group had no different survival than those with normal K-ras. However our pooled data as well as other authors' results assert that mutated K-ras constitute an additional prognostic datum that deserves to be included together with TNM classification. In the design of new preoperative (neoadjuvant) chemotherapy trials, stratification of tumors by K-ras status deserves to be further investigated in order to correlate with response, relapse and survival. Mutated K-ras genotype merits further research. Finally, the paradigm of uneven histological distribution and mutated K-ras spectra among researchers should serve as a stimulus to search for further contributions in this field.
Similar articles
-
Are RAS mutations predictive markers of resistance to standard chemotherapy?Nat Rev Clin Oncol. 2009 Sep;6(9):528-34. doi: 10.1038/nrclinonc.2009.106. Epub 2009 Jul 14. Nat Rev Clin Oncol. 2009. PMID: 19597509 Review.
-
A randomized trial of mitomycin/ifosfamide/cisplatin preoperative chemotherapy plus surgery versus surgery alone in stage IIIA non-small cell lung cancer.Semin Oncol. 1994 Jun;21(3 Suppl 4):28-33. Semin Oncol. 1994. PMID: 8209274 Clinical Trial.
-
A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.N Engl J Med. 1994 Jan 20;330(3):153-8. doi: 10.1056/NEJM199401203300301. N Engl J Med. 1994. PMID: 8043059 Clinical Trial.
-
The role of induction (neoadjuvant) chemotherapy in stage IIIA NSCLC.Chest. 1996 May;109(5 Suppl):102S-106S. doi: 10.1378/chest.109.5_supplement.102s. Chest. 1996. PMID: 8635384 Clinical Trial.
-
Across the universe of K-RAS mutations in non-small-cell-lung cancer.Curr Pharm Des. 2014;20(24):3933-43. doi: 10.2174/13816128113196660761. Curr Pharm Des. 2014. PMID: 24138715 Review.
Cited by
-
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.Clin Cancer Res. 2012 Nov 15;18(22):6169-77. doi: 10.1158/1078-0432.CCR-11-3265. Epub 2012 Sep 26. Clin Cancer Res. 2012. PMID: 23014527 Free PMC article.
-
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.Br J Cancer. 2005 Jan 17;92(1):131-9. doi: 10.1038/sj.bjc.6602258. Br J Cancer. 2005. PMID: 15597105 Free PMC article. Review.
-
Are RAS mutations predictive markers of resistance to standard chemotherapy?Nat Rev Clin Oncol. 2009 Sep;6(9):528-34. doi: 10.1038/nrclinonc.2009.106. Epub 2009 Jul 14. Nat Rev Clin Oncol. 2009. PMID: 19597509 Review.
-
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.Clin Cancer Res. 2008 Sep 15;14(18):5731-4. doi: 10.1158/1078-0432.CCR-08-0646. Clin Cancer Res. 2008. PMID: 18794081 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous